Wake Forest receives $20 million NIH grant to oversee diabetes genetics study

September 26, 2002

WINSTON-SALEM, N.C. -- Wake Forest University School of Medicine has been awarded a five-year, $20 million grant by the National Institute of Diabetes, Digestive and Kidney Diseases of the National Institutes of Health to coordinate a worldwide effort to identify the genes that determine susceptibility to Type 1 diabetes.

The project, called the international Type 1 Diabetes Genetics Consortium, will be managed by a team at the School of Medicine headed by Stephen S. Rich, Ph.D., University Professor and Vice-Chair of the Department of Public Health Sciences.

"The consortium is an ambitious global effort to identify genes contributing to Type 1 diabetes, formerly known as insulin-dependent diabetes or juvenile diabetes," said Rich.

The consortium has three main goals:
The consortium is organized into three geographical zones: North America, Europe, and Asia-Pacific. Each region will recruit volunteers, collect samples and clinical information, and perform genetic characterization. Additional geographic regions may be added.

A steering committee, chaired by Rich, will oversee operations and have representatives from each region. "The coordinating center at Wake Forest will facilitate each region's activities, will assemble the central collection of clinical information and genetic data, and will help disseminate the results of detailed genetic analysis," he said.

Rich said his team would work closely not only with the Diabetes Institute and the Juvenile Diabetes Research Foundation but also with the National Institute of Allergy and Infectious Diseases, the National Human Genome Research Institute, and other organizations to ensure the success of the consortium.

Type 1 diabetes occurs when the body's immune system malfunctions, producing an autoimmune response that destroys the insulin-producing beta cells in the pancreas. Because affected individuals no longer can produce insulin naturally, they need daily insulin injections to stay alive. The disease is often diagnosed in childhood, which is why type I diabetes was called "juvenile diabetes."

"Type 1 diabetes is caused by a complex interaction between genetics and the environment," Rich said. "Many genes are thought to contribute to a person's overall risk of developing diabetes; but some of these genes have not yet been identified."

One group of genes that determines susceptibility to the disease is termed HLA genes, which control a person's immune response. Another gene that is known to contribute to risk is the insulin gene.

"HLA and the insulin gene are not the whole story," said Rich. "As many as 17 additional genetic regions have been reported as contributing to risk. The consortium should help researchers begin to clarify the genetic picture."
-end-
Wake Forest University School of Medicine is a part of Wake Forest University Health Sciences and Wake Forest University Baptist Medical Center in Winston-Salem, N.C.. The school received more than $145 million in outside research support in the year that ended June 30. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is a part of the National Institutes of Health (NIH) and is the Federal government's lead agency for diabetes research. The Institute provided funding to begin the organization and initiation of the Type 1 Diabetes Genetics Consortium Coordinating Center at Wake Forest University School of Medicine. More information about NIDDK can be found at www.niddk.nih.gov.

The Juvenile Diabetes Research Foundation (JDRF) is the world's leading nonprofit, nongovernmental funder of diabetes research. The foundation was founded in 1970 by the parents of children with juvenile diabetes. Its mission is to find a cure for diabetes and its complications through the support of research. It provided the initial funding to help investigators organize what became the consortium. More information about JDRF can be found at www.jdrf.org.

Funding for the Consortium was made possible by appropriation of funds for Type 1 diabetes to the National Institute of Diabetes and Digestive and Kidney Diseases through the efforts of the Congressional Diabetes Caucus. Rep. Richard Burr (R-NC) is an active member of the House Diabetes Caucus, and joined 273 of his House colleagues in sending a letter to President Bush earlier this year to advocate increased funding for juvenile diabetes research.

Additional Contact Information: Jim Steele (jsteele@wfubmc.edu), Karen Richardson (krchrdsn@wfubmc.edu) or Mark Wright (mwright@wfubmc.edu) can be reached at 336-716-4587

Wake Forest Baptist Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.